Showing 1 - 19 results of 19 for search 'Julier, P', query time: 0.69s
Refine Results
-
1
CAPECITABINE (CAPE) +/- BEVACIZUMAB (BEV) IN THE ADJUVANT TREATMENT OF COLORECTAL CANCER (CRC) FIRST AND FINAL TOXICITY RESULTS FROM THE INTERNATIONAL PHASE III QUASAR2 TRIAL by Midgley, R, Love, S, Potter, V, Segelov, E, Ferry, DR, Weaver, A, Scudder, C, Julier, P, Grumett, S, Kerr, D
Published 2012Conference item -
2
VICTOR: A PHASE III PLACEBO-CONTROLLED TRIAL OF ROFECOXIB IN COLORECTAL CANCER PATIENTS FOLLOWING SURGICAL RESECTION by Midgley, R, McConkey, C, Langman, M, Smith, J, Julier, P, Iveson, C, Johnstone, E, Chen, X, Dunn, J, Kerr, D, Grp, V
Published 2008Journal article -
3
Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. by Kerr, D, Dunn, J, Langman, M, Smith, J, Midgley, R, Stanley, A, Stokes, J, Julier, P, Iveson, C, Duvvuri, R, McConkey, C
Published 2007Journal article -
4
Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory cond... by Abhishek, A, Boyton, RJ, McKnight, A, Coates, L, Barber, V, Francis, E, Appelbe, D, Julier, P, Eldridge, L, Cureton, L, Peckham, N, Cook, J
Published 2022Journal article -
5
Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. by Midgley, R, McConkey, C, Johnstone, E, Dunn, J, Smith, J, Grumett, SA, Julier, P, Iveson, C, Yanagisawa, Y, Warren, B, Langman, M, Kerr, D
Published 2010Journal article -
6
Phase II clinical trial of six mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumors. by Nicum, S, Brooks, C, Wharton, R, Boyle, L, Kaye, S, Gourley, C, Hall, M, Montes, A, Pearson, SR, Julier, P, Midgley, R, Schuh, A, Dutton, S, Grp, 6
Published 2013Journal article -
7
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial by Kerr, R, Love, S, Segelov, E, Johnstone, E, Falcon, B, Hewett, P, Weaver, A, Church, D, Scudder, C, Pearson, S, Julier, P, Pezzella, F, Tomlinson, I, Domingo, E, Kerr, D
Published 2016Journal article -
8
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial by Love, S, Kerr, R, Segelov, E, Johnstone, E, Falcon, B, Hewett, P, Weaver, A, Church, D, Scudder, C, Pearson, S, Julier, P, Pezzella, F, Tomlinson, I, Domingo, E, Kerr, D
Published 2016Journal article -
9
Hand Osteoarthritis: investigating Pain Effects in a randomised placebo-controlled feasibility study of estrogen-containing therapy (HOPE-e): report on the primary feasibility outc... by Williams, JAE, Chester-Jones, M, Francis, A, Marian, I, Goff, M, Brewer, G, Gulati, M, Eldridge, L, Julier, P, Lowe, CM, Barber, V, Glover, V, Mackworth-Young, C, Vincent, T, Lamb, SE, Vincent, K, Dutton, SJ, Watt, FE
Published 2022Conference item -
10
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a ra... by Abhishek, A, Boyton, RJ, Peckham, N, McKnight, Á, Coates, LC, Bluett, J, Barber, V, Cureton, L, Francis, A, Appelbe, D, Eldridge, L, Julier, P, Valdes, AM, Brooks, T, Rombach, I, Altmann, DM, Nguyen-Van-Tam, JS, Williams, HC, Cook, JA
Published 2022Journal article -
11
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. by Dutton, S, Ferry, D, Blazeby, J, Abbas, H, Dahle-Smith, A, Mansoor, W, Thompson, J, Harrison, M, Chatterjee, A, Falk, S, Garcia-Alonso, A, Fyfe, D, Hubner, R, Gamble, T, Peachey, L, Davoudianfar, M, Pearson, S, Julier, P, Jankowski, J, Kerr, R, Petty, R
Published 2014Journal article -
12
Patient-reported outcomes from a phase HI multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing alter chemoth... by Dutton, S, Blazeby, J, Petty, R, Mansoor, W, Thompson, J, Harrison, M, Abbas, H, Dahle-Smith, A, Chatterjee, A, Falk, S, Garcia-Alonso, A, Fyfe, D, Hubner, R, Gamble, T, Peachey, L, Harvey, C, Julier, P, Jankowski, J, Midgley, R, Ferry, DR, Grp, C
Published 2013Journal article -
13
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a ra... by Abhishek, A, Boyton, RJ, Peckham, N, McKnight, Á, Coates, LC, Bluett, J, Barber, V, Cureton, L, Francis, A, Appelbe, D, Eldridge, L, Julier, P, Valdes, AM, Brooks, T, Rombach, I, Altmann, DM, Nguyen-Van-Tam, JS, Williams, HC, Cook, JA
Published 2022Journal article -
14
Hormone replacement therapy (conjugated oestrogens plus bazedoxifene) for post-menopausal women with symptomatic hand osteoarthritis: primary report from the HOPE-e randomised, pla... by Williams, JAE, Chester-Jones, M, Minns Lowe, C, Goff, MV, Francis, A, Brewer, G, Marian, I, Morris, SL, Warwick, D, Eldridge, L, Julier, P, Gulati, M, Barker, KL, Barber, VS, Black, J, Woollacott, S, Mackworth-Young, C, Glover, V, Lamb, SE, Vincent, TL, Vincent, K, Dutton, SJ, Watt, FE
Published 2022Journal article -
15
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. by Rosmarin, D, Palles, C, Church, D, Domingo, E, Jones, A, Johnstone, E, Wang, H, Love, S, Julier, P, Scudder, C, Nicholson, G, Gonzalez-Neira, A, Martin, M, Sargent, D, Green, E, McLeod, H, Zanger, U, Schwab, M, Braun, M, Seymour, M, Thompson, L, Lacas, B, Boige, V, Ribelles, N, Afzal, S
Published 2014Journal article -
16
Two-week break in methotrexate treatment and COVID-19 vaccine response: a prospective, open label, two-arm parallel-group, multicentre, superiority, randomised controlled trial by Abhishek, A, Peckham, N, Pade, C, Gibbons, JM, Cureton, L, Francis, A, Barber, V, Williams, J, Appelbe, D, Eldridge, L, Julier, P, Altmann, DM, Bluett, J, Brooks, T, Coates, LC, Rombach, I, Semper, A, Otter, A, Valdes, AM, Nguyen-Van-Tam, JS, Williams, HC, Boyton, RJ, McKnight, Á, Cook, JA
Published 2023Journal article -
17
Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label,... by Abhishek, A, Peckham, N, Pade, C, Gibbons, JM, Cureton, L, Francis, A, Barber, V, Williams, JAE, Appelbe, D, Eldridge, L, Julier, P, Altmann, DM, Bluett, J, Brooks, T, Coates, LC, Rombach, I, Semper, A, Otter, A, Valdes, AM, Nguyen-Van-Tam, JS, Williams, HC, Boyton, RJ, McKnight, Á, Cook, JA
Published 2023Journal article -
18
A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. by Rosmarin, D, Palles, C, Pagnamenta, A, Kaur, K, Pita, G, Martin, M, Domingo, E, Jones, A, Howarth, K, Freeman-Mills, L, Johnstone, E, Wang, H, Love, S, Scudder, C, Julier, P, Fernández-Rozadilla, C, Ruiz-Ponte, C, Carracedo, A, Castellvi-Bel, S, Castells, A, Gonzalez-Neira, A, Taylor, J, Kerr, R, Kerr, D, Tomlinson, I
Published 2015Journal article -
19
A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS by Rosmarin, D, Palles, C, Pagnamenta, A, Kaur, K, Pita, G, Martin, M, Domingo, E, Jones, A, Howarth, K, Freeman-Mills, L, Johnstone, E, Wang, H, Love, S, Scudder, C, Julier, P, Fernández-Rozadilla, C, Ruiz-Ponte, C, Carracedo, A, Castellvi-Bel, S, Castells, A, Gonzalez-Neira, A, Taylor, J, Kerr, R, Kerr, D, Tomlinson, I
Published 2015Journal article